Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by Synta Pharmaceuticals and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma. Synta Pharmaceuticals announced on February 26, 2009 the suspension of all clinical trials involving Elesclomol due to safety concerns. In March 2010, Synta announced that the FDA had approved resuming clinical development of elesclomol, and that they expected to initiate one or more clinical trials for elesclomol in the second half of the year.

CAS：488832-69-5
中文别名：丙二酸-1,3-二[2-甲基-2-(苯基硫酮甲基)酰肼];
英文别名：STA-4783;1-N\',3-N\'-bis(benzenecarbonothioyl)-1-N\',3-N\'-dimethylpropanedihydrazide;Elesclomol;N-malonyl-bis(N\'-thiobenzoyl-N\'-methyl hydrazide);
分子式：C19H20N4O2S2
分子量：400.518
精确质量：400.103
Psa：128.86
Logp：2.8357

MDL号：MFCD12911784

密度：1.313
折射率：1.667